schizophrenia

News and resources

Month: September 2025

Sep 24 2025

Bristol Myers plans UK launch of schizophrenia drug Cobenfy, matching US price

by Clinical Editor

No Comments

By Sneha S K and Maggie Fick (Reuters) -Bristol Myers Squibb said on Monday it plans to launch its schizophrenia drug, Cobenfy, in the UK in 2026, and wants to...

Sep 24 2025

Neural basis of schizophrenia and bipolar disorder found in brain organoids

by Clinical Editor

No Comments

Using brain organoids, scientists discover how neurons might misfire due to schizophrenia and bipolar disorder.

Sep 23 2025

Gizmodo Science Fair: A New Pill to Treat Schizophrenia—the First in 50 Years

by Clinical Editor

No Comments

Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development of Cobenfy (xanomeline-trospium), the first truly novel medication for …

Sep 23 2025

MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug

by Clinical Editor

No Comments

The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.

Sep 22 2025

Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US

by Clinical Editor

No Comments

Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list...

Sep 22 2025

Bristol Myers Squibb aligns UK and US prices for new schizophrenia drug

by Clinical Editor

No Comments

US pharmaceutical company Bristol Myers Squibb will sell its new schizophrenia treatment in the UK for $22,500 a year, the same price as its American version, at a time when...

Sep 21 2025

The Mexican neuroscientist who is revolutionizing care for patients with psychosis – EL PAÍS English

by Clinical Editor

No Comments

The Mexican neuroscientist who is revolutionizing care for patients with psychosis EL PAÍS English

Sep 21 2025

New Long-term Safety Data from the Completed Phase 3 – GlobeNewswire

by Clinical Editor

No Comments

New Long-term Safety Data from the Completed Phase 3 GlobeNewswire

Sep 19 2025

Antipsychotic-treated patients with schizophrenia see benefits from semaglutide, study claims – Medical Xpress

by Clinical Editor

No Comments

Antipsychotic-treated patients with schizophrenia see benefits from semaglutide, study claims Medical Xpress

Sep 19 2025

Seacoast family shares details of man’s schizophrenia struggle before he died by suicide – WMUR

by Clinical Editor

No Comments

Seacoast family shares details of man’s schizophrenia struggle before he died by suicide WMUR